Current status of drug-resistant tuberculosis and its treatment.
- Author:
Jae Joon YIM
1
Author Information
1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Review
- Keywords:
Tuberculosis;
Drug resistance;
Treatment
- MeSH:
Compliance;
Drug Resistance;
Extensively Drug-Resistant Tuberculosis;
Hospitalization;
Humans;
Republic of Korea;
Tuberculosis;
Tuberculosis, Multidrug-Resistant
- From:Korean Journal of Medicine
2009;77(2):152-156
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR)-TB and extensively drug resistant (XDR)-TB, poses a serious threat to global health because it requires treatment for a long duration and frequent hospitalization, and results in a considerable number of mortalities. In South Korea, MDR is observed in 2.7% of newly diagnosed TB cases and in 14% of re-treatment cases. In addition, 5~20% of MDR-TB could be categorized as XDR-TB. Treatment regimen for MDR or XDR-TB should include 4~5 drugs susceptible to isolated tuberculous bacilli and should be maintained at least 18 months after culture conversion. Pertinent combination of anti-TB drugs and solid compliance are the basis of successful treatment for MDR and XDR-TB patients.
